Frontiers in Toxicology (Nov 2023)
Advancing chemical safety assessment through an omics-based characterization of the test system-chemical interaction
- Giusy del Giudice,
- Giusy del Giudice,
- Giusy del Giudice,
- Giusy del Giudice,
- Giorgia Migliaccio,
- Giorgia Migliaccio,
- Giorgia Migliaccio,
- Nicoletta D’Alessandro,
- Nicoletta D’Alessandro,
- Nicoletta D’Alessandro,
- Laura Aliisa Saarimäki,
- Laura Aliisa Saarimäki,
- Laura Aliisa Saarimäki,
- Laura Aliisa Saarimäki,
- Marcella Torres Maia,
- Marcella Torres Maia,
- Marcella Torres Maia,
- Maria Emilia Annala,
- Maria Emilia Annala,
- Maria Emilia Annala,
- Jenni Leppänen,
- Jenni Leppänen,
- Jenni Leppänen,
- Lena Mӧbus,
- Lena Mӧbus,
- Lena Mӧbus,
- Alisa Pavel,
- Alisa Pavel,
- Alisa Pavel,
- Maaret Vaani,
- Maaret Vaani,
- Maaret Vaani,
- Anna Vallius,
- Anna Vallius,
- Anna Vallius,
- Laura Ylä‐Outinen,
- Laura Ylä‐Outinen,
- Laura Ylä‐Outinen,
- Dario Greco,
- Dario Greco,
- Dario Greco,
- Dario Greco,
- Dario Greco,
- Angela Serra,
- Angela Serra,
- Angela Serra,
- Angela Serra,
- Angela Serra
Affiliations
- Giusy del Giudice
- Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- Giusy del Giudice
- Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Tampere, Finland
- Giusy del Giudice
- BioMediTech Unit, Tampere University, Tampere, Finland
- Giusy del Giudice
- Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
- Giorgia Migliaccio
- Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- Giorgia Migliaccio
- Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Tampere, Finland
- Giorgia Migliaccio
- BioMediTech Unit, Tampere University, Tampere, Finland
- Nicoletta D’Alessandro
- Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- Nicoletta D’Alessandro
- Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Tampere, Finland
- Nicoletta D’Alessandro
- BioMediTech Unit, Tampere University, Tampere, Finland
- Laura Aliisa Saarimäki
- Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- Laura Aliisa Saarimäki
- Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Tampere, Finland
- Laura Aliisa Saarimäki
- BioMediTech Unit, Tampere University, Tampere, Finland
- Laura Aliisa Saarimäki
- Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
- Marcella Torres Maia
- Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- Marcella Torres Maia
- Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Tampere, Finland
- Marcella Torres Maia
- BioMediTech Unit, Tampere University, Tampere, Finland
- Maria Emilia Annala
- Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- Maria Emilia Annala
- Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Tampere, Finland
- Maria Emilia Annala
- BioMediTech Unit, Tampere University, Tampere, Finland
- Jenni Leppänen
- Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- Jenni Leppänen
- Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Tampere, Finland
- Jenni Leppänen
- BioMediTech Unit, Tampere University, Tampere, Finland
- Lena Mӧbus
- Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- Lena Mӧbus
- Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Tampere, Finland
- Lena Mӧbus
- BioMediTech Unit, Tampere University, Tampere, Finland
- Alisa Pavel
- Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- Alisa Pavel
- Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Tampere, Finland
- Alisa Pavel
- BioMediTech Unit, Tampere University, Tampere, Finland
- Maaret Vaani
- Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- Maaret Vaani
- Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Tampere, Finland
- Maaret Vaani
- BioMediTech Unit, Tampere University, Tampere, Finland
- Anna Vallius
- Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- Anna Vallius
- Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Tampere, Finland
- Anna Vallius
- BioMediTech Unit, Tampere University, Tampere, Finland
- Laura Ylä‐Outinen
- Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- Laura Ylä‐Outinen
- Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Tampere, Finland
- Laura Ylä‐Outinen
- BioMediTech Unit, Tampere University, Tampere, Finland
- Dario Greco
- Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- Dario Greco
- Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Tampere, Finland
- Dario Greco
- BioMediTech Unit, Tampere University, Tampere, Finland
- Dario Greco
- Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
- Dario Greco
- Institute of Biotechnology, University of Helsinki, Helsinki, Finland
- Angela Serra
- Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
- Angela Serra
- Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Tampere, Finland
- Angela Serra
- BioMediTech Unit, Tampere University, Tampere, Finland
- Angela Serra
- Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
- Angela Serra
- Tampere Institute for Advanced Study, Tampere University, Tampere, Finland
- DOI
- https://doi.org/10.3389/ftox.2023.1294780
- Journal volume & issue
-
Vol. 5
Abstract
Assessing chemical safety is essential to evaluate the potential risks of chemical exposure to human health and the environment. Traditional methods relying on animal testing are being replaced by 3R (reduction, refinement, and replacement) principle-based alternatives, mainly depending on in vitro test methods and the Adverse Outcome Pathway framework. However, these approaches often focus on the properties of the compound, missing the broader chemical-biological interaction perspective. Currently, the lack of comprehensive molecular characterization of the in vitro test system results in limited real-world representation and contextualization of the toxicological effect under study. Leveraging omics data strengthens the understanding of the responses of different biological systems, emphasizing holistic chemical-biological interactions when developing in vitro methods. Here, we discuss the relevance of meticulous test system characterization on two safety assessment relevant scenarios and how omics-based, data-driven approaches can improve the future generation of alternative methods.
Keywords
- chemical safety assessment
- new approach methodologies
- toxicogenomics
- test system characterization
- AOP
- nanosafety